Who are sulfadoxine pyrimethamine plus piperaquine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sulfadoxine-pyrimethamine-plus-piperaquine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

sulfadoxine pyrimethamine plus piperaquine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

sulfadoxine pyrimethamine plus piperaquine (sulfadoxine pyrimethamine plus piperaquine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate antimalarial combination with quinoline antimalarial. Area: Infectious Disease.

phase 3 Antifolate antimalarial combination with quinoline antimalarial Plasmodium dihydrofolate reductase, dihydropteroate synthase, and parasite mitochondria Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

sulfadoxine pyrimethamine plus piperaquine (sulfadoxine pyrimethamine plus piperaquine) — London School of Hygiene and Tropical Medicine. This combination drug inhibits parasite folate synthesis (sulfadoxine-pyrimethamine) and disrupts parasite mitochondrial function (piperaquine) to treat malaria.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sulfadoxine pyrimethamine plus piperaquine TARGET	sulfadoxine pyrimethamine plus piperaquine	London School of Hygiene and Tropical Medicine	phase 3	Antifolate antimalarial combination with quinoline antimalarial	Plasmodium dihydrofolate reductase, dihydropteroate synthase, and parasite mitochondria

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifolate antimalarial combination with quinoline antimalarial class)

London School of Hygiene and Tropical Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sulfadoxine pyrimethamine plus piperaquine — Competitive Intelligence Brief. https://druglandscape.com/ci/sulfadoxine-pyrimethamine-plus-piperaquine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab